John Berdahl, MD

John Berdahl, MD, is with Vance Thompson Vision in Sioux Falls, South Dakota.

Articles

(Image credit: AdobeStock/MarekPhotoDesign.com)

(Part 2) From ophthalmology’s lockdown to lasting change: The pandemic habits that stuck

Sheryl Stevenson;Peter J. McDonnell;Nicole Bajic, MD;John Berdahl, MD;David A. Eichenbaum, MD;Ehsan Sadri, MD, FACS;Oluwatosin U. Smith, MD;James C. Tsai, MD, MBA

April 24th 2025

From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption

(Part 1) From ophthalmology’s lockdown to lasting change: Five Aprils ago

Sheryl Stevenson;Peter J. McDonnell, MD;Nicole Bajic, MD;John Berdahl, MD;David A. Eichenbaum, MD;Ehsan Sadri, MD, FACS;Oluwatosin U. Smith, MD;James C. Tsai, MD, MBA

April 24th 2025

Ophthalmologists reflect on the transformative impact of COVID-19, highlighting adaptations in patient care, safety protocols, and the rise of telemedicine.

Glaucoma devices and pharmaceuticals with John Berdahl, MD

John Berdahl, MD;Sydney M Crago

February 7th 2025

John Berdahl, MD, discusses a non-surgical, non-drug treatment for glaucoma approved by the FDA in 2024. The pump uses negative pressure to lower eye pressure by an average of 39% in clinical trials, with a good safety profile.

CXL demands continuity of care

John Berdahl, MD

October 15th 2017

Crosslinking meets the previously unmet needs of progressive keratoconus patients and provides an opportunity to increase engagement with optometrists, explain John Berdahl, MD, and George O. Waring IV, MD.

Exploring risk, reward in trabecular bypass, suprachoroidal devices

John Berdahl, MD

January 1st 2017

Though much focus for stents has been in the trabecular meshwork, many companies are currently developing suprachorodial devices, which are in various stages of FDA review.